Back HCV Treatment

AbbVie's Viekirax + Exviera "3D" Hepatitis C Regimen Approved in Europe

The European Commission last week approved AbbVie's interferon-free Viekirax plus Exviera combination regimen -- formerly known as "3D" -- for the treatment of genotype 1 chronic hepatitis C. This approval includes people with compensated liver cirrhosis, liver transplant recipients, HIV/HCV coinfected patients, and people on opioid substitution therapy for drug addiction. The commission also approved Viekirax plus ribavirin for HCV genotype 4.


Read more: